Key result
Sophocarpine at 20 and 40 mg/kg decreased left ventricular weight/body weight by 25.4% and 39.0% respectively, and attenuated pressure overload-induced cardiac fibrosis in rats.
Why the study?
Does sophocarpine improve cardiac fibrosis and dysfunction in rats with pressure overload-induced cardiac fibrosis?
RCT
randomly assigned
Does sophocarpine improve cardiac fibrosis and dysfunction in rats with pressure overload-induced cardiac fibrosis?
Sophocarpine demonstrates antifibrotic effects and improves cardiac function in a rat model of pressure overload, suggesting potential therapeutic value for cardiac fibrosis.
No takes yet. Share an insight, caveat, or question.
Supports further preclinical evaluation in cardiac fibrosis; leaves open translation to human heart failure therapy.
Li et al. (2014) conducted an RCT in pressure overload-induced cardiac fibrosis. Sophocarpine vs. vehicle was evaluated on left ventricular weight/body weight. Sophocarpine at 20 and 40 mg/kg decreased left ventricular weight/body weight by 25.4% and 39.0% respectively, and attenuated pressure overload-induced cardiac fibrosis in rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: